Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial

BACKGROUND: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosiborod, Mikhail N., Jhund, Pardeep S., Docherty, Kieran F., Diez, Mirta, Petrie, Mark C., Verma, Subodh, Nicolau, Jose C., Merkely, Béla, Kitakaze, Masafumi, DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Solomon, Scott D., Bengtsson, Olof, Lindholm, Daniel, Niklasson, Anna, Sjöstrand, Mikaela, Langkilde, Anna Maria, McMurray, John J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964869/
https://www.ncbi.nlm.nih.gov/pubmed/31736335
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964869/
https://www.ncbi.nlm.nih.gov/pubmed/31736335
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044138

Ejemplares similares